They will all fail. FDA will only approve, what can prove
They will all fail. FDA will only approve, what can prove direct Cardiovescular Improvements. Just improving Biomarkers is a non event. Thats why Amarin spend 500Mio $ an did a 7 years study on Cardiovescular effects.
Despite that, only the EPA has the CV effects, and AMARN has patent protection on that till 2030.
I was trading MTNB twice in the last weeks, expecting a runup beacause of Amarin. But I did intensive DD, and there was no way I would hold it longer than for the hype.
2
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
SCOR’s Actuarial Awards 2025: A Celebration of Innovation For nearly 30 years, SCOR has consistently honored exemplary research in actuarial science through its prestigious Actuarial Awards. Across six countries, these awards seek to inspire progress in the field, fostering advancements that improve our understanding of risk. Encouraging Research and Excellence The SCOR...
Continue Reading
Gentex Corporation Announces Fourth Quarter Earnings Release Gentex Corporation (NASDAQ: GNTX), a prominent supplier of advanced technology solutions including digital vision and connected car systems, has scheduled the release of its financial results for the fourth quarter and the year-end of 2024. Investors and stakeholders should mark their calendars for January 31,...
Continue Reading
Lockton's Expansion into Saudi Arabia Kansas City, Mo. – Lockton, recognized as the foremost privately held independent insurance brokerage, has embarked on a significant journey by expanding its operations into Saudi Arabia. This strategic move marks an essential development for Lockton, as it enhances its presence in the Middle East and aligns with its overarching...
Continue Reading
Partnership Between AMIAD and Dassault Aviation Leading the Way in Defense Innovation At a recent aerospace gathering, a significant partnership was forged as Pascale Lohat, the Senior Executive VP of Engineering at Dassault Aviation, and Bertrand Rondepierre, Director of the French Agency for AI in Defense (AMIAD), came together to sign a memorandum of understanding....
Continue Reading
Globus Medical, Inc. (NYSE: GMED) made waves in the orthopedic trauma sector back in 2024 with some heavy-hitting product launches. They introduced several groundbreaking systems, including the TENSOR™ Suture Button System—their first foray into suture-based innovations, which snagged 510(k) clearance from the FDA. You know that buzz on the trading floor? It was...
Continue Reading